Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer. Our transformative product candidates are – best in class – Adoptive Cell Therapies and Bispecific TCR molecules. These products are directed against tumor targets that have been identified and validated by Immatics’ proprietary and world-leading XPRESIDENT® technology. Our mission is to bring the power of T-cell redirecting immunotherapies to cancer patients.
Noile-Immune Biotech is a Tokyo-based clinical stage biotechnology company focused on the development of next generation CAR-T cells for solid tumors. Our proprietary Prime (Proliferation-inducing and migration-enhancing) CAR-T technology which express particular combination of IL-7 and CCL19, is designed to enhance anti-tumor potential by enabling infiltration, accumulation, and survival of CAR-T cells in coordination with activation of tumor-reactive host T cells and their memory formation. Read more here.